Real-world surgical outcomes of a gelatin-hemostatic matrix in women requiring a hysterectomy: A matched case–control study
Obermair, Helena, Janda, Monika, & Obermair, Andreas (2016) Real-world surgical outcomes of a gelatin-hemostatic matrix in women requiring a hysterectomy: A matched case–control study. Acta Obstetricia et Gynecologica Scandinavica, 95(9), pp. 1008-1014.
Administrators only until September 2017 | Request a copy from author
The aim of this study was to compare adverse events and surgical outcomes of hysterectomy with or without use of a gelatin-hemostatic matrix (SURGIFLO®).
Materials and Methods
Prospective case-control study (Canadian Task Force classification II2) of total hysterectomy (Piver Type 1) provided by surgeons in Australia between Nov 2005 and May 2015. Data were collected via SurgicalPerformance, a web-based data project which aims to provide confidential feedback to surgeons about their surgical outcomes. Of 2,440 records of women who received a hysterectomy, 1,351 were eligible for these analyses, 107 received SURGIFLO® hemostatic matrix to prevent postoperative blood loss and 1,244 did not receive SURGIFLO®.
Patients with or without SURGIFLO® differed in age, Charlson co-morbidity index, and American Society of Anesthesiologists physical status classification system score (ASA), and also differed in clinical outcomes. After matching for patient’s age and ASA at surgery, patients with and without SURGIFLO® had comparable baseline characteristics. Matched patients with and without SURGIFLO® had comparable clinical outcomes including risk of developing vault hematoma, return to the operating room, transfusion of red cells, surgical site infection (pelvis), readmission within 30 days and unplanned ICU admission.
In a sample matched by age and ASA, SURGIFLO® neither prevents nor causes additional adverse events in women undergoing hysterectomy. Surgeons used SURGIFLO® more commonly among women who were older, had more comorbidities and a higher ASA score. This indicates that it may be most useful in complicated surgery or cases.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||hysterectomy, adverse events, surgical outcomes, SURGIFLO® gelatin-hemostatic matrix|
|Subjects:||Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000)
Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > PUBLIC HEALTH AND HEALTH SERVICES (111700)
Australian and New Zealand Standard Research Classification
|Divisions:||Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
Current > Schools > School of Public Health & Social Work
|Copyright Owner:||Copyright 2016 Nordic Federation of Societies of Obstetrics and Gynecology|
|Copyright Statement:||This is the peer reviewed version of the following article: Obermair H, Janda M, Obermair A. Real-world surgical outcomes of a gelatin-hemostatic matrix in women requiring a hysterectomy: a matched case–control study. Acta Obstet Gynecol Scand 2016; 95:1008–1014, which has been published in final form at https://doi.org/10.1111/aogs.12924. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.|
|Deposited On:||16 Aug 2016 22:42|
|Last Modified:||23 Aug 2016 16:18|
Repository Staff Only: item control page